PP86 Cost Effectiveness Of Maternal Respiratory Syncytial Virus (RSV) Prefusion F (RSVpreF) With Complementary Nirsevimab Versus Nirsevimab Alone For Preventing RSV Among Infants In Chile
Rafael Bolaños, Juan Francisco Falconi, Ahuva Averin, Erin Quinn, Amy Law, Diana Mendes · 2025
Read PP86 Cost Effectiveness Of Maternal Respiratory Syncytial Virus (RSV) Prefusion F (RSVpreF) With Complementary Nirsevimab Versus Nirsevimab Alone For Preventing RSV Among Infants In Chile by Rafael Bolaños, Juan Francisco Falconi, Ahuva Averin, Erin Quinn, Amy Law, Diana Mendes (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768832.txt.
Description
Rafael Bolaños and five co-authors weigh two ways to protect infants in Chile from respiratory syncytial virus, or RSV. One plan gives the maternal RSVpreF vaccine plus nirsevimab only to infants of unvaccinated mothers. The other gives nirsevimab alone, the approach Chile recommended for infants in 2023. A cohort model tracks illness, deaths, and costs from birth to age one, plus lifetime effects of RSV deaths.
The model uses uptake of 90 percent and a nirsevimab price of USD260.00. Without any intervention, it projects 10,457 hospital cases and 39,460 emergency visits. Results are reported from both healthcare system and societal perspectives, with costs in 2023 dollars.
Catalog record
| CREATOR | Rafael Bolaños, Juan Francisco Falconi, Ahuva Averin, Erin Quinn, Amy Law, Diana Mendes |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |